Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO6799477 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Healthy Volunteers | EXPERIMENTAL | - |
| Part 2: Patients with T2D, Group A | EXPERIMENTAL | Low dose daily oral administration of RO6799477 |
| Part 2: Patients with T2D, Group B | EXPERIMENTAL | High dose daily oral administration of RO6799477 |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Matching placebo daily oral administration |
| RO6799477 | DRUG | Daily oral administration of RO6799477 |
Inclusion Criteria: Part 1 Inclusion criteria: * Right-handed male volunteers * Aged 18-45 years, inclusive * Healthy participants, as determined by screening assessments and Principal Investigator's judgment * Healthy status is defined by the absence of evidence of any active or chronic disease f...
Top 16 of 30 competitors
RO6799477 is an investigational small molecule developed by Roche Holding AG for Type 2 Diabetes. It is a Phase 1 clinical candidate in the metabolic therapeutic area. It has been studied in a single completed Phase 1 trial that enrolled 40 participants, including healthy volunteers and patients with Type 2 Diabetes Mellitus.
RO6799477 is being developed as a treatment for Type 2 Diabetes. It has been evaluated in a Phase 1 study that included patients with Type 2 Diabetes Mellitus alongside healthy volunteers. The program remains investigational and has not been approved for any indication.
RO6799477 is developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating the compound in Type 2 Diabetes and in healthy volunteers.
RO6799477 is in Phase 1 clinical development. Its only recorded trial, NCT02164266, was a Phase 1 study that has been completed. The compound is investigational and has not been approved by the FDA or any other regulatory agency for Type 2 Diabetes or any other indication.
RO6799477 has been studied in one clinical trial, NCT02164266, titled a study of the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of RO6799477. The Phase 1 trial was completed, enrolled 40 participants, was randomized, double blind, and controlled, and was conducted in the Netherlands.